Anthony H Dickenson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9020857/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neuropharmacological basis for multimodal analgesia in chronic pain. Postgraduate Medicine, 2022, 134, 245-259.	0.9	13
2	Ambroxol for neuropathic pain: hiding in plain sight?. Pain, 2022, Publish Ahead of Print, .	2.0	2
3	Why are sodium channel modulators not yet pharmacotherapeutic trailblazers for neuropathic pain?. Expert Opinion on Pharmacotherapy, 2021, 22, 1635-1637.	0.9	3
4	Studying independent Kcna6 knock-out mice reveals toxicity of exogenous LacZ to central nociceptor terminals and differential effects of Kv1.6 on acute and neuropathic pain sensation. Journal of Neuroscience, 2021, 41, JN-RM-0187-21.	1.7	5
5	What goes up must come down: insights from studies on descending controls acting on spinal pain processing. Journal of Neural Transmission, 2020, 127, 541-549.	1.4	22
6	A study of cortical and brainstem mechanisms of diffuse noxious inhibitory controls in anaesthetised normal and neuropathic rats. European Journal of Neuroscience, 2020, 51, 952-962.	1.2	10
7	Neuropathic Pain: Mechanism-Based Therapeutics. Annual Review of Pharmacology and Toxicology, 2020, 60, 257-274.	4.2	129
8	Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?. Current Medical Research and Opinion, 2020, 36, (I)-(XVII).	0.9	2
9	Selective modulation of tonic aversive qualities of neuropathic pain by morphine in the central nucleus of the amygdala requires endogenous opioid signaling in the anterior cingulate cortex. Pain, 2020, 161, 609-618.	2.0	34
10	The impact of bone cancer on the peripheral encoding of mechanical pressure stimuli. Pain, 2020, 161, 1894-1905.	2.0	13
11	Capsaicin 8% dermal patch in clinical practice: an expert opinion. Expert Opinion on Pharmacotherapy, 2020, 21, 1377-1387.	0.9	29
12	Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?. Current Medical Research and Opinion, 2020, 36, 1015-1024.	0.9	5
13	Translational issues in precision medicine in neuropathic pain. Canadian Journal of Pain, 2020, 4, 30-38.	0.6	17
14	Unusual Pain Disorders – What Can Be Learned from Them?. Journal of Pain Research, 2020, Volume 13, 3539-3554.	0.8	3
15	Supraspinal Opioid Circuits Differentially Modulate Spinal Neuronal Responses in Neuropathic Rats. Anesthesiology, 2020, 132, 881-894.	1.3	10
16	GPR160 de-orphanization reveals critical roles in neuropathic pain in rodents. Journal of Clinical Investigation, 2020, 130, 2587-2592.	3.9	62
17	Neuropathy following spinal nerve injury shares features with the irritable nociceptor phenotype: A backâ€ŧranslational study of oxcarbazepine. European Journal of Pain, 2019, 23, 183-197.	1.4	23
18	Sigmaâ€l receptor modulates neuroinflammation associated with mechanical hypersensitivity and opioid tolerance in a mouse model of osteoarthritis pain. British Journal of Pharmacology, 2019, 176, 3939-3955.	2.7	26

#	Article	IF	CITATIONS
19	The neurobiology of chronic pain states. Anaesthesia and Intensive Care Medicine, 2019, 20, 426-429.	0.1	0
20	Issues in the future development of new analgesic drugs. Current Opinion in Supportive and Palliative Care, 2019, 13, 107-110.	0.5	3
21	Novel insights on the management of pain: highlights from the †Science of Relief' meeting. Pain Management, 2019, 9, 521-533.	0.7	9
22	Pharmacological rationale for tapentadol therapy: a review of new evidence. Journal of Pain Research, 2019, Volume 12, 1513-1520.	0.8	28
23	<p>Tapentadol: a new option for the treatment of cancer and noncancer pain</p> . Journal of Pain Research, 2019, Volume 12, 1509-1511.	0.8	6
24	A combination pharmacotherapy of tapentadol and pregabalin to tackle centrally driven osteoarthritis pain. European Journal of Pain, 2019, 23, 1185-1195.	1.4	17
25	Kappa opioid signaling in the right central amygdala causes hind paw specific loss of diffuse noxious inhibitory controls in experimental neuropathic pain. Pain, 2019, 160, 1614-1621.	2.0	45
26	Editorial for Pain: Nonmalignant Diseases in 2018. Current Opinion in Supportive and Palliative Care, 2018, 12, 131.	0.5	0
27	Editorial for Pain: Cancer in 2018. Current Opinion in Supportive and Palliative Care, 2018, 12, 101.	0.5	0
28	Immune or Genetic-Mediated Disruption of CASPR2 Causes Pain Hypersensitivity Due to Enhanced Primary Afferent Excitability. Neuron, 2018, 97, 806-822.e10.	3.8	119
29	Holding down the pain. Brain, 2018, 141, 5-6.	3.7	2
30	Calcium channel modulation as a target in chronic pain control. British Journal of Pharmacology, 2018, 175, 2173-2184.	2.7	77
31	Sense and sensibility—logical approaches to profiling in animal models. Pain, 2018, 159, 1426-1428.	2.0	9
32	Modality selective roles of pro-nociceptive spinal 5-HT2A and 5-HT3 receptors in normal and neuropathic states. Neuropharmacology, 2018, 143, 29-37.	2.0	28
33	Morphine effects within the rodent anterior cingulate cortex and rostral ventromedial medulla reveal separable modulation of affective and sensory qualities of acute or chronic pain. Pain, 2018, 159, 2512-2521.	2.0	46
34	Selective deficiencies in descending inhibitory modulation in neuropathic rats: implications for enhancing noradrenergic tone. Pain, 2018, 159, 1887-1899.	2.0	23
35	Neuropathic pain. Nature Reviews Disease Primers, 2017, 3, 17002.	18.1	1,360
36	Hopes for the Future of Pain Control. Pain and Therapy, 2017, 6, 117-128.	1.5	42

#	Article	IF	CITATIONS
37	Sensory processing of deep tissue nociception in the rat spinal cord and thalamic ventrobasal complex. Physiological Reports, 2017, 5, e13323.	0.7	19
38	Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain. Pain, 2017, 158, 2386-2395.	2.0	74
39	Effect of the spider toxin Tx3-3 on spinal processing of sensory information in naive and neuropathic rats: an in vivo electrophysiological study. Pain Reports, 2017, 2, e610.	1.4	11
40	Editorial. Current Opinion in Supportive and Palliative Care, 2017, 11, 105.	0.5	0
41	Making sense of sensory profiles. Pain, 2016, 157, 1177-1178.	2.0	3
42	What the brain tells the spinal cord. Pain, 2016, 157, 2148-2151.	2.0	41
43	What do monoamines do in pain modulation?. Current Opinion in Supportive and Palliative Care, 2016, 10, 143-148.	0.5	92
44	Special 10th anniversary editorial. Current Opinion in Supportive and Palliative Care, 2016, 10, 2.	0.5	0
45	Neuronal hyperexcitability in the ventral posterior thalamus of neuropathic rats: modality selective effects of pregabalin. Journal of Neurophysiology, 2016, 116, 159-170.	0.9	38
46	Is tapentadol different from classical opioids? A review of the evidence. British Journal of Pain, 2016, 10, 217-221.	0.7	72
47	Mechanisms of the gabapentinoids and <i>α</i> ₂ <i>δ</i> â€1 calcium channel subunit in neuropathic pain. Pharmacology Research and Perspectives, 2016, 4, e00205.	1.1	186
48	Effects of intraplantar botulinum toxinâ€B on carrageenanâ€induced changes in nociception and spinal phosphorylation of GluA1 and Akt. European Journal of Neuroscience, 2016, 44, 1714-1722.	1.2	6
49	Scratching the surface: the processing of pain from deep tissues. Pain Management, 2016, 6, 95-102.	0.7	8
50	Evidence for spinal N-methyl-d-aspartate receptor involvement in prolonged chemical nociception in the rat. Brain Research, 2016, 1645, 58-60.	1.1	143
51	Ionic mechanisms of spinal neuronal cold hypersensitivity in ciguatera. European Journal of Neuroscience, 2015, 42, 3004-3011.	1.2	13
52	Human psychophysics and rodent spinal neurones exhibit peripheral and central mechanisms of inflammatory pain in the UVB and UVB heat rekindling models. Journal of Physiology, 2015, 593, 4029-4042.	1.3	26
53	Pain. Current Opinion in Supportive and Palliative Care, 2015, 9, 97.	0.5	1
54	Diffuse noxious inhibitory controls and nerve injury. Pain, 2015, 156, 1803-1811.	2.0	137

#	Article	IF	CITATIONS
55	Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. Brain, 2015, 138, 28-35.	3.7	120
56	Towards the Development of New Pain Treatments. Journal of Pain and Palliative Care Pharmacotherapy, 2015, 29, 56-58.	0.5	0
57	The influence of μ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy. European Journal of Pharmacology, 2015, 749, 151-160.	1.7	16
58	Synergistic Effect of 5-Hydroxytryptamine 3 and Neurokinin 1 Receptor Antagonism in Rodent Models of Somatic and Visceral Pain. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 146-152.	1.3	22
59	Cancer pain physiology. British Journal of Pain, 2014, 8, 154-162.	0.7	36
60	Differential upregulation in DRG neurons of an α2Î′-1 splice variant with a lower affinity for gabapentin after peripheral sensory nerve injury. Pain, 2014, 155, 522-533.	2.0	36
61	Can we stop pain before it starts?. Pain, 2014, 155, 208-209.	2.0	2
62	Emerging drugs for neuropathic pain. Expert Opinion on Emerging Drugs, 2014, 19, 329-341.	1.0	62
63	Anti-hyperalgesic effects of a novel TRPM8 agonist in neuropathic rats: A comparison with topical menthol. Pain, 2014, 155, 2097-2107.	2.0	37
64	Neuropathic plasticity in the opioid and non-opioid actions of dynorphin A fragments and their interactions with bradykinin B2 receptors on neuronal activity in the rat spinal cord. Neuropharmacology, 2014, 85, 375-383.	2.0	27
65	Novel TRPM8 Antagonist Attenuates Cold Hypersensitivity after Peripheral Nerve Injury in Rats. Journal of Pharmacology and Experimental Therapeutics, 2014, 349, 47-55.	1.3	28
66	Pain and Nociception: Mechanisms of Cancer-Induced Bone Pain. Journal of Clinical Oncology, 2014, 32, 1647-1654.	0.8	249
67	Morphine sensitivity of spinal neurons in the chronic constriction injury neuropathic rat pain model. Neuroscience Letters, 2014, 562, 97-101.	1.0	15
68	Osteoarthritis pain: nociceptive or neuropathic?. Nature Reviews Rheumatology, 2014, 10, 374-380.	3.5	195
69	Commentary on: Opioid and noradrenergic contributions of tapentadol in experimental neuropathic pain. Neuroscience Letters, 2014, 562, 90.	1.0	2
70	Mechanisms and Management of Diabetic Painful Distal Symmetrical Polyneuropathy. Diabetes Care, 2013, 36, 2456-2465.	4.3	252
71	Peripheral input and its importance for central sensitization. Annals of Neurology, 2013, 74, 630-636.	2.8	202
72	Combination pharmacotherapy for management of chronic pain: from bench to bedside. Lancet Neurology, The, 2013, 12, 1084-1095.	4.9	212

#	Article	IF	CITATIONS
73	Neural coding of nociceptive stimuli—from rat spinal neurones to human perception. Pain, 2013, 154, 1263-1273.	2.0	61
74	Genes, molecules and patients—Emerging topics to guide clinical pain research. European Journal of Pharmacology, 2013, 716, 188-202.	1.7	11
75	The Antinociceptive Effect of Milnacipran in the Monosodium Iodoacetate Model of Osteoarthritis Pain and Its Relation to Changes in Descending Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 696-707.	1.3	22
76	α ₂ δ-1 Gene Deletion Affects Somatosensory Neuron Function and Delays Mechanical Hypersensitivity in Response to Peripheral Nerve Damage. Journal of Neuroscience, 2013, 33, 16412-16426.	1.7	105
77	Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. Nature Communications, 2012, 3, 791.	5.8	228
78	Asymmetric timeâ€dependent activation of right central amygdala neurones in rats with peripheral neuropathy and pregabalin modulation. European Journal of Neuroscience, 2012, 36, 3204-3213.	1.2	92
79	Unravelling the Mystery of Capsaicin: A Tool to Understand and Treat Pain. Pharmacological Reviews, 2012, 64, 939-971.	7.1	271
80	The double cross of morphine: Stopping OIH in its tracks. Annals of Palliative Medicine, 2012, 1, 4-5.	0.5	0
81	Mu-opioid and noradrenergic α2-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain, 2011, 152, 131-139.	2.0	72
82	Descending controls: Insurance against pain?. Pain, 2011, 152, 2677-2678.	2.0	2
83	Recent Developments in Neuropathic Pain Mechanisms: Implications for Treatment. Reviews in Pain, 2011, 5, 21-25.	0.2	7
84	Perturbing PSD-95 Interactions With NR2B-subtype Receptors Attenuates Spinal Nociceptive Plasticity and Neuropathic Pain. Molecular Therapy, 2011, 19, 1780-1792.	3.7	80
85	Opioid hyperalgesia. Current Opinion in Supportive and Palliative Care, 2010, 4, 1-5.	0.5	56
86	Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats. Brain, 2010, 133, 2549-2564.	3.7	110
87	Descending serotonergic facilitation mediated by spinal 5-HT3 receptors engages spinal rapamycin-sensitive pathways in the rat. Neuroscience Letters, 2010, 484, 108-112.	1.0	18
88	Mammalian Target of Rapamycin Signaling in the Spinal Cord Is Required for Neuronal Plasticity and Behavioral Hypersensitivity Associated With Neuropathy in the Rat. Journal of Pain, 2010, 11, 1356-1367.	0.7	77
89	A selective role for α3 subunit glycine receptors in inflammatory pain. Frontiers in Molecular Neuroscience, 2009, 2, 14.	1.4	37
90	The Increased Trafficking of the Calcium Channel Subunit α ₂ δ-1 to Presynaptic Terminals in Neuropathic Pain Is Inhibited by the α ₂ δ Ligand Pregabalin. Journal of Neuroscience, 2009, 29, 4076-4088.	1.7	372

#	Article	IF	CITATIONS
91	Preclinical and Early Clinical Investigations Related to Monoaminergic Pain Modulation. Neurotherapeutics, 2009, 6, 703-712.	2.1	132
92	Effects of lacosamide, a novel sodium channel modulator, on dorsal horn neuronal responses in a rat model of neuropathy. Neuropharmacology, 2009, 57, 472-479.	2.0	22
93	Descending Serotonergic Facilitation and the Antinociceptive Effects of Pregabalin in a Rat Model of Osteoarthritic Pain. Molecular Pain, 2009, 5, 1744-8069-5-45.	1.0	116
94	Formalin-Induced Behavioural Hypersensitivity and Neuronal Hyperexcitability are Mediated by Rapid Protein Synthesis at the Spinal Level. Molecular Pain, 2009, 5, 1744-8069-5-27.	1.0	76
95	Fibromyalgia: Harmonizing Science with Clinical Practice Considerations. Pain Practice, 2008, 8, 177-189.	0.9	74
96	Peripheral Nerve Injury–Induced Changes in Spinal α2-Adrenoceptor–Mediated Modulation of Mechanically Evoked Dorsal Horn Neuronal Responses. Journal of Pain, 2008, 9, 350-359.	0.7	62
97	Selective ablation of dorsal horn NK1 expressing cells reveals a modulation of spinal alpha2-adrenergic inhibition of dorsal horn neurones. Neuropharmacology, 2008, 54, 1208-1214.	2.0	20
98	Descending facilitation from the brainstem determines behavioural and neuronal hypersensitivity following nerve injury and efficacy of pregabalin. Pain, 2008, 140, 209-223.	2.0	106
99	Mechanisms of pain in nonmalignant disease. Current Opinion in Supportive and Palliative Care, 2008, 2, 133-139.	0.5	19
100	Neuropathic pain: multiple mechanisms at multiple sites. Future Neurology, 2007, 2, 661-671.	0.9	6
101	Evidence for spinal dorsal horn hyperexcitability in rats following sustained morphine exposure. Neuroscience Letters, 2006, 407, 156-161.	1.0	23
102	Differential pharmacological modulation of the spontaneous stimulus-independent activity in the rat spinal cord following peripheral nerve injury. Experimental Neurology, 2006, 198, 72-80.	2.0	64
103	Depletion of endogenous spinal 5-HT attenuates the behavioural hypersensitivity to mechanical and cooling stimuli induced by spinal nerve ligation. Pain, 2006, 123, 264-274.	2.0	102
104	Calcium channel α2δ1 subunit mediates spinal hyperexcitability in pain modulation. Pain, 2006, 125, 20-34.	2.0	231
105	Gabapentin Normalizes Spinal Neuronal Responses That Correlate with Behavior in a Rat Model of Cancer-induced Bone Pain. Anesthesiology, 2005, 102, 132-140.	1.3	115
106	Opioids in neuropathic pain: clues from animal studies. European Journal of Pain, 2005, 9, 113-116.	1.4	37
107	Oxytocin actions on afferent evoked spinal cord neuronal activities in neuropathic but not in normal rats. Brain Research, 2005, 1045, 124-133.	1.1	68
108	Pains, gains, and midbrains. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17885-17886.	3.3	17

#	Article	IF	CITATIONS
109	Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. Pain, 2005, 117, 292-303.	2.0	150
110	Efficacy of Chronic Morphine in a Rat Model of Cancer-Induced Bone Pain: Behavior and in Dorsal Horn Pathophysiology. Journal of Pain, 2005, 6, 837-845.	0.7	45
111	Cholecystokinin fails to block the spinal inhibitory effects of nociceptin in sham operated and neuropathic rats. European Journal of Pharmacology, 2004, 484, 235-240.	1.7	7
112	Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurones following peripheral nerve injury. Brain Research, 2004, 1019, 68-76.	1.1	188
113	Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends in Pharmacological Sciences, 2004, 25, 613-617.	4.0	438
114	Descending serotonergic facilitation mediated through rat spinal 5HT3 receptors is unaltered following carrageenan inflammation. Neuroscience Letters, 2004, 361, 229-231.	1.0	62
115	Does a Single Intravenous Injection of the 5HT3 Receptor Antagonist Ondansetron Have an Analgesic Effect in Neuropathic Pain? A Double-Blinded, Placebo-Controlled Cross-Over Study. Anesthesia and Analgesia, 2003, 97, 1474-1478.	1.1	118
116	KCNQ/M Currents in Sensory Neurons: Significance for Pain Therapy. Journal of Neuroscience, 2003, 23, 7227-7236.	1.7	323
117	A Combination of Gabapentin and Morphine Mediates Enhanced Inhibitory Effects on Dorsal Horn Neuronal Responses in a Rat Model of Neuropathy. Anesthesiology, 2002, 96, 633-640.	1.3	126
118	The Pharmacology of Central Sensitization. Journal of Musculoskeletal Pain, 2002, 10, 35-43.	0.3	2
119	Neuropharmacologic targets and agents in fibromyalgia. Current Pain and Headache Reports, 2002, 6, 267-273.	1.3	2
120	Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nature Neuroscience, 2002, 5, 1319-1326.	7.1	389
121	Neurobiology of neuropathic pain: mode of action of anticonvulsants. European Journal of Pain, 2002, 6, 51-60.	1.4	105
122	6-Substituted 2-azabicyclo[2.2.1]hept-5-enes by hitrogen-directed radical rearrangement: synthesis of an epibatidine analogue with high binding affinity at the nicotinic acetylcholine receptorElectronic supplementary information (ESI) available: details of biological studies. See http://www.rsc.org/suppdata/p1/b1/b107414h/. Journal of the Chemical Society, Perkin Transactions 1,	1.3	25
123	Comparison of the effects of MK-801, ketamine and memantine on responses of spinal dorsal horn neurones in a rat model of mononeuropathy. Pain, 2001, 91, 101-109.	2.0	110
124	Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain, 2001, 92, 235-246.	2.0	169
125	Amino acids are still as exciting as ever. Current Opinion in Pharmacology, 2001, 1, 57-61.	1.7	21

#	Article	IF	CITATIONS
127	The effect of ABT-702, a novel adenosine kinase inhibitor, on the responses of spinal neurones following carrageenan inflammation and peripheral nerve injury. British Journal of Pharmacology, 2001, 132, 1615-1623.	2.7	35
128	Neuropathic pain. NeuroReport, 2000, 11, R17-R21.	0.6	59
129	Effects of spinally administered P2X receptor agonists and antagonists on the responses of dorsal horn neurones recorded in normal, carrageenan-inflamed and neuropathic rats. British Journal of Pharmacology, 2000, 129, 351-359.	2.7	49
130	Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature, 2000, 407, 1015-1017.	13.7	421
131	Neuronal inhibitory effects of methadone are predominantly opioid receptor mediated in the rat spinal cord in vivo. European Journal of Pain, 2000, 4, 19-26.	1.4	30
132	An excitatory role for 5-HT in spinal inflammatory nociceptive transmission; state-dependent actions via dorsal horn 5-HT3 receptors in the anaesthetized rat. Pain, 2000, 89, 81-88.	2.0	123
133	Effects of midazolam in the spinal nerve ligation model of neuropathic pain in rats. Pain, 2000, 85, 425-431.	2.0	43
134	Different increase in C-fibre evoked responses after nociceptive conditioning stimulation in sham-operated and neuropathic rats. Neuroscience Letters, 2000, 288, 99-102.	1.0	32
135	Adenosine as a Potential Analgesic Target in Inflammatory and Neuropathic Pains. CNS Drugs, 2000, 13, 77-85.	2.7	53
136	The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nature Neuroscience, 1999, 2, 541-548.	7.1	739
137	Electrophysiological studies on the postnatal development of the spinal antinociceptive effects of the delta opioid receptor agonist DPDPE in the rat. British Journal of Pharmacology, 1999, 126, 1115-1122.	2.7	8
138	The effectiveness of spinal and systemic morphine on rat dorsal horn neuronal responses in the spinal nerve ligation model of neuropathic pain. Pain, 1999, 80, 215-228.	2.0	90
139	Electrophysiological characterization of spinal neuronal response properties in anaesthetized rats after ligation of spinal nerves L5-L6. Journal of Physiology, 1998, 507, 881-894.	1.3	157
140	Evidence that [Phe1 Ï^(CH2 -NH)Gly2]nociceptin-(1-13)-NH2 , a peripheral ORL-1 receptor antagonist, acts as an agonist in the rat spinal cord. British Journal of Pharmacology, 1998, 125, 949-952.	2.7	52
141	Spinal Effects of Bicuculline: Modulation of an Allodynia-Like State by an A1-Receptor Agonist, Morphine, and an NMDA-Receptor Antagonist. Journal of Neurophysiology, 1998, 79, 1494-1507.	0.9	50
142	Pains, brains, and opium. Behavioral and Brain Sciences, 1997, 20, 479-482.	0.4	0
143	Plasticity: Implications for opioid and other pharmacological interventions in specific pain states. Behavioral and Brain Sciences, 1997, 20, 392-403.	0.4	59
144	Distinct inhibitory effects of spinal endomorphin-1 and endomorphin-2 on evoked dorsal horn neuronal responses in the rat. British Journal of Pharmacology, 1997, 122, 1537-1539.	2.7	61

#	Article	IF	CITATIONS
145	The Role of Ketamine, an NMDA Receptor Antagonist, in the Management of Pain. Progress in Palliative Care, 1995, 3, 127-134.	0.7	38
146	Central Acute Pain Mechanisms. Annals of Medicine, 1995, 27, 223-227.	1.5	72
147	Electrophysiological study on spinal antinociceptive interactions between adenosine and morphine in the dorsal horn of the rat. Neuroscience Letters, 1995, 194, 81-84.	1.0	14
148	The roles of spinal adenosine receptors in the control of acute and more persistent nociceptive responses of dorsal horn neurones in the anaesthetized rat. British Journal of Pharmacology, 1995, 116, 2221-2228.	2.7	127
149	Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation. British Journal of Pharmacology, 1993, 108, 967-973.	2.7	81
150	Combination therapy in analgesia; seeking synergy. Current Opinion in Anaesthesiology, 1993, 6, 861-865???866.	0.9	35
151	Alterations in neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan-induced inflammation. Pain, 1992, 50, 345-354.	2.0	137
152	NMDA receptors and central hyperalgesic states. Pain, 1991, 46, 344-345.	2.0	26
153	A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends in Pharmacological Sciences, 1990, 11, 307-309.	4.0	292
154	Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre or post formalin. Pain, 1987, 30, 349-360.	2.0	483
155	Lack of evidence for increased descending inhibition on the dorsal horn of the rat following periaqueductal grey morphine microinjections. British Journal of Pharmacology, 1987, 92, 271-280.	2.7	22
156	Electrophysiological studies on the effects of intrathecal morphine on nociceptive neurones in the rat dorsal horn. Pain, 1986, 24, 211-222.	2.0	227
157	Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. Pain, 1979, 6, 283-304.	2.0	1,177
158	Diffuse noxious inhibitory controls (DNIC). II. Lack of effect on non-convergent neurones, supraspinal involvement and theoretical implications. Pain, 1979, 6, 305-327.	2.0	679
159	Role of the nucleus raphe magnus in opiate analgesia as studied by the microinjection technique in the rat. Brain Research, 1979, 170, 95-111.	1.1	252
160	Peptides. , 0, , 251-264.		0
161	Pain and Analgesia. , 0, , 453-474.		1
162	Amino Acids: Excitatory. , 0, , 211-223.		3

3

#	Article	IF	CITATIONS
163	Drug Dependence and Abuse. , 0, , 499-520.		3

164 Other Transmitters and Mediators. , 0, , 265-286.